Prothena Corporation plc (PRTA)
Develops antibody drugs to treat Parkinson's, Alzheimer's, and other brain diseases
$8.56-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+25.7%
The outlook
Prothena is trading near its 52-week lows, well below its short and long-term averages. Analysts lean bullish with an average target about 150% above the current price, though coverage is modest at five analysts. The stock sits in the lower portion of its yearly range, reflecting recent weakness despite the constructive analyst view.
What’s behind the score
Analyst consensusBuy — 2.5 avg of 5 analysts
Price trendBelow its 50- & 200-day averages
52-week range38% of the way from its 52-week low to high
Price targetAvg target +150% vs current price
Analyst price target
~12-month · 5 analysts$21.40average target+150.0% vs now
Now $8.56
Low $8.00High $36.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$448.1M
52-wk high
$11.80
52-wk low
$6.61
50-day avg
$9.15
200-day avg
$9.67
Trailing P/E
—